BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Lokelma (Sodium zirconium cyclosilicate) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Lokelma (Sodium zirconium cyclosilicate)\
 , from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06578078-608@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Lokelma (Sodium zirconium cyclosilicate): Phase 3 readout est. (NCT
 06578078)
DESCRIPTION:Lokelma (Sodium zirconium cyclosilicate)\, phase 3\, Chronic Ki
 dney Disease.\nStudy: A Clinical Trial to Define the Best Strategy for the
  Management of Heart Failure in Elderly Patients\nEstimated primary comple
 tion: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/sodium-zirconium-cyclosilicate#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06578078
URL:https://assetmemo.bio/drug/sodium-zirconium-cyclosilicate#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06736184-608@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lokelma (Sodium zirconium cyclosilicate): Phase 4 readout est. (NCT
 06736184)
DESCRIPTION:Lokelma (Sodium zirconium cyclosilicate)\, phase 4\, Chronic Ki
 dney Disease.\nStudy: the Cardioprotective Effects of Improving Potassium 
 Variability in Maintenance Hemodialysis Patients\nEstimated primary comple
 tion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/sodium-zirconium-cyclosilicate#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06736184
URL:https://assetmemo.bio/drug/sodium-zirconium-cyclosilicate#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06578533-608@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Lokelma (Sodium zirconium cyclosilicate): Phase 3 readout est. (NCT
 06578533)
DESCRIPTION:Lokelma (Sodium zirconium cyclosilicate)\, phase 3\, Chronic Ki
 dney Disease.\nStudy: Keeping RAASi Treatment With Optimal Potassium Contr
 ol\nEstimated primary completion: 30 July 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/sodium-zirconium-cyclosilicate#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06578533
URL:https://assetmemo.bio/drug/sodium-zirconium-cyclosilicate#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03813407-608@assetmemo.bio
DTSTAMP:20261121T004957Z
DTSTART;VALUE=DATE:20300221
DTEND;VALUE=DATE:20300222
SUMMARY:Lokelma (Sodium zirconium cyclosilicate): Phase 3 readout est. (NCT
 03813407)
DESCRIPTION:Lokelma (Sodium zirconium cyclosilicate)\, phase 3.\nStudy: An 
 Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patien
 ts With Hyperkalaemia\nEstimated primary completion: 21 February 2030. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/sodium-zirconium-cyclosi
 licate#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT03813407
URL:https://assetmemo.bio/drug/sodium-zirconium-cyclosilicate#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
